在"十四五"与"十五五"规划衔接的关键阶段,乡村振兴与县域经济发展已成为国家战略的重点。在此背 景下,龙头企业如何与地方经济深度融合、实现共同成长,成为检验其社会价值与商业韧性的重要标尺。 1月5日,八马茶业在福州发布"双第一·六连冠"纳税成绩单:连续13年位居安溪茶企纳税榜首,连续6年蝉联 武夷山茶企纳税第一。这一成绩不仅创造了茶行业罕见的"纳税双冠·六连冠"纪录,更揭示了一家龙头企 业如何通过系统性战略,在实现商业成功的同时,深度赋能产区,构建可持续的产业共生生态。 纳税"双冠"本质:市场认可的财务投影 在商业经济逻辑中,纳税额常被视为企业市场地位的"财务镜像"。八马茶业连续六年稳居安溪、武夷山 两大核心茶产区纳税榜首,其背后是企业强劲的市场表现与品牌号召力。 根据弗若斯特沙利文报告,按2024年销售收入计,八马茶业在中国乌龙茶和红茶市场排名第一。截至2024 年公司的铁观音销量连续10多年位居全国第一、岩茶销量连续5年位居全国第一、红茶销量连续4年位居 全国第一。其市场地位直接转化为企业营收与税收贡献,形成了"销量领先—业绩增长—纳税贡献"的良 性循环。 八马茶业董事长王文礼在发布会上表示,纳税第一"并 ...

新华社香港1月3日电 题：香港"拆弹专家"的无声守护 新华社记者孟佳 0:00 "拆弹专家"李展超如今还清楚地记得，2025年9月19日夜里，空气中那股紧张与潮湿的味道。 暴雨滂沱、警灯闪烁，香港鲗鱼涌附近的一片工地被封锁线围住。当天，这里发现了一枚重达1千磅的二战遗留美军空投炸弹。 炸弹的引信状态未明；工地附近高楼林立、人员密集；台风"桦加沙"即将袭来……作为香港警务处爆炸品处理课高级炸弹处理主任，李展超第一 时间来到现场坐镇指挥。多年的经验让他意识到事态的严重性，他和队员当即做出判断：没有时间转移炸弹，需要立即疏散居民，进行现场销 毁。 "我作为当天值班的炸弹处理主任，责无旁贷。"张立得说。仔细检查后，看到里面的炸药已经燃烧殆尽，他向不远处的队友们比出OK的手势—— 炸弹被安全销毁。 每一位在场人员鼓掌欢呼，城市恢复了往日的喧嚣。 回顾香港爆炸品处理课半个多世纪的发展，李展超说，从早期沿用英式体系，到如今引入内地科研力量，已经形成了兼具国际标准与本地经验的 专业体系。 "以前我们国家的技术还落后，这些年，已经追上甚至超过很多国家。"他介绍，自2020年起，香港警队全面启用国产排爆机器人与AI识别系统， 科 ...

冬至的乳山,海风微寒,银滩大酒店里却暖意融融。12月21日上午,"冬至乳山畅品牡蛎"第三季暨"蚝聚乳 山链动未来"产业推广活动在此启动。参加活动的有产业链上的养殖户、企业负责人、电商主播、科研 专家,还有从各地赶来的客商。他们共同关注的焦点,是桌上那只饱满肥美的乳山牡蛎。 从最初论堆卖的"海产",到如今贴上防伪标签、按个售卖的"品牌商品",再到布局预制菜、进军营养品和 护肤品赛道的"产业明星",乳山牡蛎的蜕变,映射出威海乳山农业特色产业从"产得出"到"卖得好"、从"卖 原料"到"卖品牌"的深刻转型。 记者潘佳蓬威海报道 从论堆卖到论个卖 "2017年我刚担任乳山市牡蛎协会秘书长时,市场上打着'乳山牡蛎'名号的产品鱼龙混杂,真假难辨,价格也 上不去。"活动现场,乳山市牡蛎协会秘书长刘卫国回忆起品牌保护之初的艰难时这样说道。 转变始于2021年。协会引进了国际首创的液体可变色防伪技术,为每一件乳山牡蛎产品贴上可溯源查询 的"身份证"。同时,协会聘请专业机构开展维权打假,对数百起侵权行为提起诉讼。 效果立竿见影。"实施防伪溯源后,线上平台搜索'乳山牡蛎',排名前十的店铺中我们的正品占比从30%提 升到90%以上,销 ...

Core Insights - The event "Winter Solstice Lushun Oyster Tasting" marks the third season of promoting Lushun oysters, highlighting the transformation of the local oyster industry from raw material sales to branded products and value-added offerings [1][3]. Industry Transformation - Lushun oysters have evolved from being sold in bulk to being branded products with anti-counterfeiting measures, reflecting a significant shift in the local agricultural industry [3]. - The introduction of liquid color-changing anti-counterfeiting technology in 2021 has improved product authenticity, increasing the proportion of genuine products sold online from 30% to over 90% [4][6]. - The average price of Lushun oysters has risen by 20% to 30% due to brand protection efforts, which have attracted quality enterprises to invest in the region [6]. Technological Advancements - Scientific research and development have played a crucial role in enhancing oyster quality and production efficiency, with local universities contributing to breeding and health monitoring [9][11]. - The introduction of new oyster varieties and health management practices has improved survival rates and overall quality, reducing annual losses in the industry by approximately 200 to 300 million yuan [12]. Sales and Marketing Innovations - E-commerce and live streaming have revolutionized the sales process, allowing Lushun oysters to reach a broader market and increasing production standards [13]. - The nutritional benefits of Lushun oysters have been emphasized, with high protein and zinc content being highlighted by health experts [13]. Collaborative Development - A demonstration area for integrated oyster industry development has been established, promoting collective management and benefiting local communities through job creation and income generation [14]. - The project has attracted investments from local villagers and social capital, fostering a cooperative model that enhances brand value and mitigates market risks [14]. Future Outlook - The brand value of Lushun oysters reached 19.385 billion yuan in 2023, showcasing the potential for further growth through innovation and market integration [15]. - The industry is positioned as a model for high-quality rural development, emphasizing the importance of maintaining quality and health standards while leveraging technology and market forces [15].

近年来，随着中国等新兴经济体产业水平的快速提升，国际经贸关系正从过去的"互补"关系，迈向 "竞 争中合作共赢" 的新常态。这种"竞合"关系已成为现代文明的新标识。在此背景下，亚太地区作为全球 最具活力的经济区域，持续引领全球经济增长。为适应这一新格局，制度型开放变得至关重要。主动对 接国际高标准经贸规则，打造稳定、透明的开放环境，成为共享发展红利、推动包容性增长的关键。 专业团队与语种覆盖支撑复杂需求 面对全球性会议涉及的广泛议题与多元参会者，强大的译员资源库和语种覆盖能力不可或缺。业内服务 商通常建有覆盖全球主要语种及部分小语种的译员网络，核心同传译员需持有如ATA、NAATI、CATTI 等国内外权威认证，并在金融、科技、法律等垂直领域具备深厚的知识背景。 以信实翻译公司为例，其公开资料显示团队语言覆盖范围较广，能够处理多语种会议需求，并通过与高 校共建人才培养基地等方式，持续进行专业资源储备。同时，其长期服务多家国内外大型企业的案例， 也为其积累了处理复杂国际会议的经验。 行业观察：从"人才依赖"到"系统保障"的转变 同声传译作为国际会议、高端论坛的核心支持环节，其服务成效直接影响跨国沟通的精准与效率。 ...

Investment Rating - The report indicates a strong growth potential for the bird's nest peptide industry, with a projected market expansion from 2.17 billion CNY in 2022 to 16 billion CNY by 2029, reflecting a compound annual growth rate (CAGR) of 35.47% [8][9]. Core Insights - The bird's nest peptide industry is characterized by high biological activity and absorption, driven by technological innovations and a focus on modern biotechnology to enhance product efficacy [5][6]. - The market is evolving from research exploration to industrialization, with significant growth observed since 2018, particularly in product forms and applications [7]. - Demand is primarily driven by high-income consumers seeking precise nutrition and health benefits, with brands employing multi-channel strategies to enhance market penetration [11]. Market Background - Bird's nest peptides are derived from edible bird's nests through hydrolysis, resulting in small molecular peptides with high bioactivity [5]. - The industry has transitioned from academic research to commercialization, with key technological advancements facilitating this shift [7]. Market Status - The market size is expected to grow significantly, with a CAGR of 28.62% from 2022 to 2024, and an anticipated acceleration to 35.47% from 2025 to 2029 [8][9]. - Supply is characterized by high technical barriers and concentration among leading brands, with significant reliance on patented processes for production [10]. - Demand is robust, driven by middle to high-income consumers, with brands leveraging both online and offline channels for effective market reach [11]. Market Competition - The competitive landscape is defined by leading companies like Zheng Dian Yan Wo and Yan Zhi Wu, which have established significant barriers through raw material control and proprietary technologies [13]. - The competition has evolved from product-based to a comprehensive evaluation of supply chain control, technological innovation, and multi-scenario applications [13]. - The report highlights ten recommended brands, each with unique strengths in product quality, technological innovation, and market positioning [14][15][16]. Development Trends - The industry is moving towards technological, functional, and standardized advancements, with a focus on cross-industry integration [17]. - Companies are increasingly investing in research to validate health benefits scientifically, shifting from concept marketing to evidence-based claims [17]. - The report emphasizes the importance of comprehensive capabilities in research, technology barriers, and innovative applications for future market leadership [17].

宇树科技(Unitree)创始人兼CEO王兴兴作为新理事代表发言，他对亚布力论坛思想改变世界的理念表示 强烈认同，并表示，思想是引领前行的方向，技术是筑牢发展的基石，二者路径各异，初心一致，宇树 科技愿与亚布力论坛携手共进，共同为改变世界贡献力量。 12月2日，亚布力中国企业家论坛2025年理事会在线上顺利召开，会议由亚布力论坛理事长、泰康保险 集团股份有限公司创始人、董事长兼CEO陈东升主持。经亚布力论坛2024-2026年度轮值主席、滴灌通 集团创始人及主席李小加提名，理事会全票表决通过，58同城董事长兼CEO姚劲波当选亚布力论坛2026 年度联席轮值主席。与此同时，经理事会严格审核讨论，亚布力论坛也迎来宇树科技(Unitree)创始人兼 CEO王兴兴，中信资本董事长张懿宸，爱康集团创始人、董事长兼CEO张黎刚三位新理事。 会上，李小加主席作年度工作总结。过去一年，他带领亚布力论坛圆满举办了2月年会、6月中美商业领 袖圆桌会议、7月创新年会、9月夏季年会等多场大型会议及活动。同时，李小加直面论坛现存问题，针 对性地提出2026年要加强新一代领导力的培养以及企业家的培育、提升论坛内容的丰富性与对话高效 性、 ...

来源：亚布力企业家论坛CEF 12月2日，亚布力中国企业家论坛2025年理事会在线上顺利召开，会议由亚布力论坛理事长、泰康保险 集团股份有限公司创始人、董事长兼CEO陈东升主持。 经亚布力论坛2024-2026年度轮值主席、滴灌通集团创始人及主席李小加提名，理事会全票表决通过， 58同城董事长兼CEO姚劲波当选亚布力论坛2026年度联席轮值主席。与此同时，经理事会严格审核讨 论，亚布力论坛也迎来宇树科技（Unitree）创始人兼CEO王兴兴，中信资本董事长张懿宸，爱康集团创 始人、董事长兼CEO张黎刚三位新理事。 会上，李小加主席作年度工作总结。过去一年，他带领亚布力论坛圆满举办了2月年会、6月中美商业领 袖圆桌会议、7月创新年会、9月夏季年会等多场大型会议及活动。同时，李小加直面论坛现存问题，针 对性地提出2026年要加强新一代领导力的培养以及企业家的培育、提升论坛内容的丰富性与对话高效 性、推动国际间企业家交流与合作等改进方向。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 亚布力论坛2026年度联席轮值主席、58同城董事长兼CEO姚劲波发表当选致辞。姚劲波对理事会给予的 信任 ...

Group 1 - The "2026 World Strawberry Expo and Strawberry Industry Exchange Conference" will be held in Hangzhou, China, on January 7-8, 2026, focusing on "New Models, New Products, High Quality" [2] - The event aims to attract 500 industry professionals, corporate representatives, and experts from both domestic and international markets to discuss technological innovation and sustainable development in the strawberry industry [2] - The conference will feature representatives from countries such as Russia, South Korea, Azerbaijan, and Georgia, promoting global resource integration and cooperation [2] Group 2 - The event will cover the entire strawberry industry chain, including planting, processing, sales, and distribution, with several key cooperation projects and activity segments [4] - Specific projects include the procurement of greenhouse construction in Russia's Far East, complete equipment for factory cultivation, strawberry sorting and packaging, and autumn strawberry seedling procurement [4] - Additional activities will include the procurement of new strawberry varieties, a tasting event for new strawberry varieties, and a comprehensive exhibition of the strawberry industry [5] Group 3 - The conference will gather government agencies, planting enterprises, buyers (supermarkets, fresh e-commerce, wholesale markets), restaurants, hotels, and industry media to create a closed-loop of production and sales [7] - The expo aims to promote the strawberry industry towards standardization, branding, and technological upgrades through international collaboration, injecting new momentum into the global strawberry industry [7] - The event will celebrate the 20th anniversary of China's participation in the World Strawberry Conference, inviting past participants to share highlights from previous conferences [7]

会上，白云山稀核健康与全球医疗科技巨头GE医疗签署战略合作协议，双方将致力在精准医疗与核医 学领域的发展与创新，为充分发挥白云山稀核健康在放射性药物研发、生产与管理专业优势，以及GE 医疗深厚的技术沉淀，推动医学影像前沿技术的提升及转化，共同引领核医学诊疗一体化的发展。此次 合作既是广药集团"科技化""国际化"战略的具体实践，也是跨界资源整合、推动产业升级的重要探索。 白云山稀核健康此次发布的完全自主知识产权医用放射性核素一体化解决方案，成功攻克固体靶系统与 分离纯化技术壁垒，构建了从辐照到核素制备的全链条技术体系；同步推出的镓-68、锆-89、铼-186与 铜-64四大核心医用核素，涵盖精准诊断、靶向治疗及诊疗一体化方向，标志着广药集团已能完全自 主、稳定地制备上述四种关键医用放射性核素以及在多核素药物研发平台的建设上取得了决定性突破。 中证报中证网讯（王珞）11月18日，2025年广药集团、广药白云山（600332）战略合作研讨会在南京举 办。大会汇聚合作伙伴、行业专家及企业代表等430余位嘉宾，搭建起覆盖医药大健康全产业链的高端 对话与资源对接平台，集中发布了广药集团创新战略、创新成果与合作规划，其中核 ...